Who owns the alpelisib synthesis patent connected to Novartis (2009)?
Alpelisib is a Novartis-developed oncology drug. Public patent databases and filings around alpelisib include multiple patent “families” that cover different aspects of the invention, such as the compound itself, formulations, and manufacturing/synthesis methods. The specific “2009 alpelisib synthesis patent” typically refers to a synthesis/manufacturing-related patent filing date or publication tied to Novartis (often through one or more corporate entities in the Novartis group).
How to find the exact Novartis 2009 alpelisib synthesis patent number
Because “2009 alpelisib synthesis patent” can map to more than one document (different applicants, publication numbers, or related family members), the fastest way to pinpoint the exact patent is to search by:
- Drug name: “alpelisib”
- Applicant/assignee: “Novartis” (or Novartis entities)
- Patent type/keyword: “process,” “manufacturing,” “preparation,” “synthesis”
- Year filter: 2009
If you want, share any one of the following you’ve seen (even partially), and I can help narrow to the exact patent record: a publication number (e.g., WO/EP/US), an inventor name, or a snippet of the title/abstract.
When was the key alpelisib (Piqray) manufacturing/synthesis IP filed and published?
Synthesis/process patents are often filed before or around the time compounds advance into clinical development, then published later (commonly 18 months after priority). So a “2009” reference usually points to an underlying filing/priority year, while the publicly visible publication may appear later.
What does a “synthesis/process” patent cover for alpelisib?
A synthesis patent generally covers one or more steps or routes to make alpelisib (and sometimes key intermediates). Claims commonly focus on:
- Specific chemical transformations or reaction conditions
- Use of particular reagents/catalysts
- Routes that produce a defined intermediate or final compound
- Purification steps that affect yield or impurity profile
These method claims can affect generic or biosimilar-style “manufacturing design-around” efforts, even if another party has a different way to obtain the same drug substance.
Are there other related patents besides synthesis from the same era?
Yes. For alpelisib, patent protection has historically spanned multiple categories, so a “synthesis” patent alone may not reflect the full protection picture (for example, you can also see patents covering polymorphs, formulations, and use). This is why investors and competitors usually track the whole patent landscape rather than a single “process” document.
Want a ready-to-use source link?
DrugPatentWatch.com often tracks drug-related patent assignments and listings, which can help you locate the specific alpelisib patent records (including those connected to manufacturing/process). Use this search page as a starting point: https://www.drugpatentwatch.com/patent/ (then search “alpelisib” and filter by Novartis and process/synthesis terms).
---
Sources
- DrugPatentWatch.com